Unilife has developed two new technologies for delivering injectable therapies to targeted regions of the eye.
The new technologies include Unilife Depot-Ject platform which allows clinicians to implant a solid or oil based drug into the eye,which releases an active pharmaceutical compound for a long duration of time.
Other technology includes the Unilife Ocu-Ject platform which delivers microliter sized doses into the eye,thus reducing the risk of over-dosing or under-dosing.
Unilife CEO Alan Shortall said since the start of an ongoing collaboration with a pharmaceutical company to develop a targeted organ delivery device,the company has identified many additional areas where it has been able to leverage its proprietary technologies to address other unmet customer needs.
"There are many acute and chronic diseases that have been recognized by pharmaceutical companies as attractive areas for investment where the absence of a suitable delivery system has impeded the commercialization and widespread clinical adoption of promising injectable therapies,"Shortall added.
"Our innovative device solutions for drug depot deployment and microliter dosing offer a wide range of opportunities to improve patient comfort and safety,optimize clinician convenience,and enable or enhance the commercialization of drugs designed for targeted or localized delivery to many areas of the body,including the eye."